The concurrent association of inflammatory polymyositis and Crohn’s ileo-colitis in a Sri Lankan man: a case report of a rare association and literature review
© Bataduwaarachchi et al.; licensee BioMed Central Ltd. 2014
Received: 22 July 2013
Accepted: 17 February 2014
Published: 20 February 2014
Crohn’s disease is a relapsing, systemic inflammatory disease affecting the gastrointestinal tract with associated extraintestinal manifestations and immune disorders. Among the few cases reported, the association of Crohn’s disease with polymyositis varies in its complexity and severity. We report here the first known case of inflammatory polymyositis leading to rhabdomyolysis in a male patient diagnosed with Crohn’s ileocolitis.
A 42-year-old previously healthy man presented with acute polymyositis leading to rhabdomyolysis. The acute nature of the illness raised the suspicion of an infective, toxic, or metabolic insult, which was excluded during further investigations. Prolonged low-grade fever and raised inflammatory markers led to the suspicion of inflammatory polymyositis, which was confirmed by electromyography and muscle histology. In the absence of an infective cause, the concurrent association of prolonged diarrhea containing blood and mucous after recovery from an acute phase of myositis proved a diagnostic challenge. Ileocolonoscopy findings of extensive aphthous ulceration with skip lesions extending to the terminal ileum, and histology showing polymorph infiltration of the lamina propria, transmural involvement, and micro abscess formation was suggestive of Crohn’s disease. Sensory motor axonal peripheral neuropathy, which is another rare association of inflammatory bowel disease, was also present.
An unrecognized genetic predisposition or altered gut permeability causing disruption of the gut immune barrier triggering an immune response against skeletal muscles may have contributed to this unique association. Both polymyositis and Crohn’s ileocolitis responded well to corticosteroids and azathioprine, which is supportive of their immune pathogenesis. Myositis can be considered to be a rare extraintestinal manifestation of Crohn’s disease and can be used in the differential diagnosis of corticosteroid or hypokalemia-induced myopathy in Crohn’s disease.
KeywordsInflammatory polymyositis Crohn’s disease Rhabdomyolysis Ileocolitis
Crohn’s disease (CD) is a relapsing systemic inflammatory disease that predominantly affects the gastrointestinal tract. Its association with extraintestinal manifestations is complex, causing many diagnostic and management challenges. Seronegative spondyloarthropathies have been reported in 33% of CD patients , while erythema nodosum is more common in CD than pyoderma gangrenosum . Episcleritis, scleritis, and uveitis occur in approximately 3% of patients with inflammatory bowel disease (IBD) and are more often seen in patients with ulcerative colitis than CD [3, 4]. Primary sclerosing cholangitis, thromboembolic events, and nephrolithiasis are less common associations of IBD. Moreover, peripheral neuropathy is not well characterized in IBD and its incidence varies from 0.9 to 3.6% [5, 6]. Chronic idiopathic inflammatory myopathy (IIM) is also a rare association with CD, with one known study by Szabo et al. of a female CD patient presenting with chronic IIM .
Few cases have reported an association of polymyositis with CD, although the occurrence of polymyositis, alopecia universalis, and primary sclerosing cholangitis was observed in a male CD patient in Germany , and Hall documented a case of focal myositis involving the left gastrocnemius muscle . The timing of the onset of myositis has been shown to vary widely among patients with IBD [10–12]. Only a small number of cases of rhabdomyolysis in association with CD have been reported, of which the subclinical presentation is more common than the acute presentation . Most of these were caused by hypokalemia associated with severe IBD, and only one case report describes probable immune pathogenesis [10, 14–16]. The study of different disease associations will provide new insights into the complex pathogenesis of IBD, and expansion of the scope of extraintestinal manifestations will aid the early diagnosis and management of CD. We herein report the first known case of inflammatory polymyositis complicated with rhabdomyolysis in a male patient diagnosed with CD.
A 42-year-old previously healthy man was admitted to the emergency department with sudden-onset right upper limb swelling, pain, and weakness associated with dysphagia, reduced urine output, red-colored urine, and melena. He had consumed three pints of alcohol 3 days prior to this presentation but had no history of travel, trauma, or illicit drug abuse. He had acidotic breathing on examination.
A full blood count showed severe anemia, thrombocytopenia, and neutrophil leukocytosis. The inflammatory markers, erythrocyte sedimentation rate and C-reactive protein levels were well above the normal range, which was suggestive of an inflammatory process. The full urine report confirmed myoglobulinuria. Creatine kinase levels exceded 50,000 U/L, and serum myoglobin levels were more than 60,000 ng/mL, which was suggestive of rhabdomyolysis. Clinical and biochemical parameters confirmed acute kidney injury (AKI). Aspartate transaminase levels (4,795 U/L, normal range 8–48 U/L) exceeded alanine transaminase (ALT) levels, and were 100 times the normal level, which explained the leakage from muscle damage. ALT levels were also 40 times the normal level (2,268 U/l, normal range 7–55 U/L), with associated high activated partial thromboplastin time and prothrombin time indicating simultaneous liver injury. D-dimer levels were within normal limits and disseminated intravascular coagulation was excluded. Arterial and venous Doppler scans of the upper limbs excluded thrombosis as the cause of severe edema and revealed marked subcutaneous and soft tissue edema. Initial diagnosis suggested an acute metabolic, toxic, or infective insult causing myositis and rhabdomyolysis leading to AKI.
Once the diagnosis of inflammatory polymyositis and CD was established, prednisolone and azathioprine doses were increased to 1 mg/kg (60 mg) daily and 2.5 mg/kg (150 mg), respectively, as the bowel symptoms of the patient continued while on therapy for myositis. Mesacol® (mesalamine), 400 mg daily, and the probiotic Florastor, 250 mg twice daily, were added to the treatment regimen at the same time. Metronidazole was not added in the presence of neuropathy and in the absence of septic complications. The patient achieved clinical remission in both conditions, which was evidenced by the settling of diarrhea and fever, improvement of muscle strength, and significant weight gain by the third week of treatment. Corticosteroid treatment was reduced by 10 mg twice weekly once the endoscopic remission of CD was confirmed. Mesalamine (mesalazine) and Florastor were discontinued and the patient was kept on an azathioprine maintenance dose of 150 mg daily one month after starting treatment. Special attention was given to the patient’s nutrition as his muscles were affected by both the disease process and poor nutrition. A gradual improvement of renal function was followed by an improvement of myositis, which was attributed to the recovery of acute tubular necrosis, secondary to heavy myoglobinuria.
CD is known to have different immunopathogenic mechanisms; therefore, although the serum markers were negative, an autoimmune disorder remained the most likely possibility in this patient. The observed rapid response to corticosteroids and immunosuppressants also favored this hypothesis. However, the concurrent presentation of two different relapsing inflammatory disorders in a male patient with no family history is unusual. Cuoco previously reported significantly increased blood tumor necrosis factor-α and sphingosine levels caused by enhanced lipopolysaccharide concentration (p < 0.01) resulting from altered gut permeability (p < 0.01) causing a reduction in muscle fiber size . We suggest that a similar mechanism contributed to the development of an immune response against skeletal muscle in the present case.
Myositis is considered a rare extraintestinal manifestation of CD, but may in fact be a more common occurrence than is reported in patients with IBD. A suggestion for physicians to carefully monitor muscle pain and serum creatine kinase (CK) levels in patients with IBD was previously made by Al-Kawas . Moreover, myositis should be strongly suspected in CD patients with muscle weakness and elevated CK levels, which may help in the early diagnosis and appropriate treatment of CD. Immune-mediated myositis should be considered as an important differential diagnosis for myopathy occurring in IBD secondary to hypokalemia or corticosteroid treatment . In this case, the acute phase of myositis preceded the symptoms of Crohn’s colitis, revealing it to be a separate entity with an inflammatory origin compared with hypokalemia or corticosteroid-induced myopathy.
The immune-mediated pathogenesis of both conditions contributed to their rapid remission following immunosuppressant treatment in our patient. Another study showed that when myositis in CD is immune mediated, the treatment of bowel inflammation should be emphasized as opposed to corticosteroid or other immunosuppressive therapy . In this case, complete recovery of both myositis and CD was achieved with a combination of prednisolone, azathioprine, and mesalamine treatment. The specific effect of mesalamine in this patient cannot be assessed as it was added while increasing the doses of prednisolone and azathioprine.
Myositis and CD together cause profound effects on muscle biology because of their immune-mediateddamage, and nutritional and metabolic deficiencies. Therefore, overall patient management should give equal emphasis to achieving remission as well as correcting metabolic derangements and nutrition. In addition, hypokalemia should be closely monitored and corticosteroids should be used cautiously in this unique association as they can contribute to further muscle injury.
The occurrence of immune polymyositis in CD has a probable related pathophysiological mechanism. Alterations of bowel mucosal permeability causing disruption of the gut-immune barrier may have triggered an immune response against skeletal muscle, which warrants further investigations. Standard immune modulators used in CD such as prednisolone and azathioprine are effective first-line therapies to induce remission in both conditions. Immune-mediated myositis is an important differential diagnosis for hypokalemia or corticosteroid-induced myopathy, and muscle biopsy plays an important role in its differentiation. This case provides new insights into disease pathogenesis and useful evidence for the management of CD associated with immune polymyositis.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
VRB: (MBBS, pursuing MD (medicine)). Registrar in medicine, National Hospital, Colombo, Sri Lanka.
NF: (MBBS, MD (medicine), MRCP). Senior registrar in gastroenterology, National Hospital, Colombo, Sri Lanka.
UL: (MBBS, MD (medicine), MRCP, FRACP). Senior registrar in medicine, Sri Jayawardanapura General Hospital, Colombo, Sri Lanka.
CJ: (MBBS, MD (medicine)). Consultant physician, Sri Jayawardanapura General Hospital, Colombo, Sri Lanka.
Inflammatory bowel disease
Acute kidney injury
Hematoxylin and eosin stain
We thank Dr. Ekanayake for the preparation of histology slides and interpretation; Dr. Chula Herath for contributing to the management of acute kidney injury. We also thank Professor R L Satharasinghe for important management inputs during clinical decision making of this patient.
- Orchard T, Wordsworth B, Jewell D: Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998, 42 (3): 387-391. 10.1136/gut.42.3.387.View ArticlePubMedPubMed CentralGoogle Scholar
- Rothfuss K, Stange E, Herrlinger K: Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006, 12 (30): 4819-4831.PubMedPubMed CentralGoogle Scholar
- Lakatos L, Pandur T, David G, Balogh Z, Kuronya P, Tollas A, Lakatos PL: Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol. 2003, 9 (10): 2300-2307.View ArticlePubMedPubMed CentralGoogle Scholar
- Rankin G, Watts H, Melnyk C, Kelley ML J: National cooperative Crohn’s disease study: extraintestinal manifestations and perianal complications. Gastroenterology. 1979, 77 (2): 4-920.Google Scholar
- Lossos A, River Y, Eliakim A, Steiner I: Neurologic aspects of inflammatory bowel disease. Neurology. 1995, 45 (3): 416-421. 10.1212/WNL.45.3.416.View ArticlePubMedGoogle Scholar
- Elsehety A, Bertorini T: Neurologic and neuropsychiatric complications of Crohn’s disease. South Med J. 1997, 90 (6): 606-610. 10.1097/00007611-199706000-00005.View ArticlePubMedGoogle Scholar
- Szabo N, Lukacs S, Kulcsar I, Gunasekera W, Nagy-Toldi A, Dezso B, Danko K: Association of idiopathic inflammatory myopathy and Crohn’s disease. Clin Rheumatol. 2009, 28 (1): 99-101. 10.1007/s10067-008-1032-8.View ArticlePubMedGoogle Scholar
- Seibold F, Klein R, Jakob F: Polymyositis, alopecia universalis, and primary sclerosing cholangitis in a patient with Crohn’s disease. J Clin Gastroenterol. 1996, 23 (2): 121-124. 10.1097/00004836-199609000-00011.View ArticlePubMedGoogle Scholar
- Hall J, Thomas E, Cooper T: Gastrocnemius myositis in a patient with inflammatory bowel disease. Digestion. 1985, 32 (4): 296-300. 10.1159/000199251.View ArticlePubMedGoogle Scholar
- Shimoyama T, Tamura Y, Sakamoto T, Inoue K: Immune-mediated myositis in Crohn’s disease. Muscle Nerve. 2009, 39 (1): 101-105. 10.1002/mus.21164.View ArticlePubMedGoogle Scholar
- Braun-Moscovici Y, Schapira D, Balbir-Gurman A, Nahir M: Inflammatory bowel disease and myositis. Clin Rheumatol. 1999, 18 (3): 261-263. 10.1007/s100670050097.View ArticlePubMedGoogle Scholar
- Al-Kawas H: Myositis associated with Crohn’s colitis. Am J Gastroenterol. 1986, 81 (7): 583-585.PubMedGoogle Scholar
- Chiba M, Igarashi K, Ohta H, Ohtaka M, Arakawa H, Masamune O: Rhabdomyolysis associated with Crohn’s disease. Jpn J Med. 1987, 26 (2): 255-260. 10.2169/internalmedicine1962.26.255.View ArticlePubMedGoogle Scholar
- Mangonea M, Spagnoloa A, Capursoa G, Marignania M, Panzutoa F, Angelettia S, Ruggeria M, Menèb P, Delle Favea G: Rhabdomyolysis due to severe hypokaliemia in a Crohn’s disease patient after budesonide treatment. Dig Liver Dis. 2007, 39 (8): 776-779. 10.1016/j.dld.2006.09.003.View ArticleGoogle Scholar
- Matsuda T, Inoue S, Furuya H: Rhabdomyolysis associated with Crohn’s disease, probably mediated by myositis. A & A. 2005, 100 (3): 898-Google Scholar
- Cuoco L, Vescovo G, Castaman R, Ravara B, Cammarota G, Angelini A, Salvagnini M, Libera LD: Skeletal muscle wastage in Crohn’s disease: a pathway shared with heart failure?. Int J Cardiol. 2008, 127 (2): 219-227. 10.1016/j.ijcard.2007.06.006.View ArticlePubMedGoogle Scholar
- Podolsky D: Inflammatory bowel disease. N Engl J Med. 2002, 347 (6): 417-429. 10.1056/NEJMra020831.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/14/35/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.